ArticleBMC cardiovascular disorders2026
Association between glycemic variability and mortality after coronary stent implantation in critically ill patients: a retrospective cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGlycemic variability (GV) has been associated with adverse outcomes in critical illness; however, its prognostic relevance in patients undergoing coronary stent implantation remains unclear.
methodsIn this retrospective cohort study, we analyzed 2,427 adult patients who underwent coronary stent implantation and were admitted to the coronary care unit (CCU) or cardiovascular intensive care unit (CVICU) using data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Glycemic variability (GV) was defined as the coefficient of variation of blood glucose (standard deviation/mean ×100%). The primary and secondary outcomes were in-hospital and 365-day all-cause mortality. Associations were assessed using multivariable Cox models. Nonlinear relationships, survival differences, discriminative ability, and mediation effects were evaluated using restricted cubic splines, Kaplan-Meier analysis, time-dependent receiver operating characteristic (ROC) curves, and mediation analysis, respectively. External validation was performed in the eICU Collaborative Research Database.
resultsPatients in the highest GV quartile had significantly higher risks of in-hospital mortality (HR 2.58, 95% CI 1.30, 5.13) and 365-day mortality (HR 1.77, 95% CI 1.20, 2.60) compared with those in the lowest quartile. A significant trend across GV quartiles was observed (p for trend < 0.01), although excess risk was primarily driven by the highest quartile. These associations were consistent across analyses and were externally validated. Mediation analysis indicated that blood urea nitrogen accounted for 7.7% and 10.3% of the association, respectively.
conclusionsElevated glycemic variability (GV) was independently associated with increased risks of in-hospital and 365-day all-cause mortality after coronary stent implantation. GV may serve as a simple and clinically accessible marker for risk stratification in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.